ArticleJournal of molecular and cellular cardiology2020
Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs.
Open access · greenAbstract read
In one paragraph
Article in Journal of molecular and cellular cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- PLN-L31A/I40A for the treatment of inherited heart disease caused by PLN-R14del mutations.Acta pharmacologica Sinica · 2026Article
- Multiparametric imaging of spatio-temporal cAMP signaling, transmembrane potential, and intracellular calcium in the intact heart.iScience · 2026Article
- Calcium handling remodeling in dilated cardiomyopathy: From molecular mechanisms to targeted therapies.Channels (Austin, Tex.) · 2025Review
- Intercellular NETwork-facilitated sarcoplasmic reticulum targeting for myocardial ischemia-reperfusion injury treatment.Science advances · 2025Article
- Mechanisms for cardiac calcium pump activation by its substrate and a synthetic allosteric modulator using fluorescence lifetime imaging.PNAS nexus · 2024Article
- Article
- Phospholamban R14del disease: The past, the present and the future.Frontiers in cardiovascular medicine · 2023Review
- Cardiac calcium regulation in human induced pluripotent stem cell cardiomyocytes: Implications for disease modeling and maturation.Frontiers in cell and developmental biology · 2022Review
- Genetic Cardiomyopathies: The Lesson Learned from hiPSCs.Journal of clinical medicine · 2021Review
- Circular RNA Expression for Dilated Cardiomyopathy in Hearts and Pluripotent Stem Cell-Derived Cardiomyocytes.Frontiers in cell and developmental biology · 2021Review
- Protein docking and steered molecular dynamics suggest alternative phospholamban-binding sites on the SERCA calcium transporter.The Journal of biological chemistry · 2020Article
- Linking Biochemical and Structural States of SERCA: Achievements, Challenges, and New Opportunities.International journal of molecular sciences · 2020Review
- Modeling Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D Cultures.International journal of molecular sciences · 2020Review
- Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy.Frontiers in physiology · 2020Review
- The transmembrane peptide DWORF activates SERCA2a via dual mechanisms.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Daniel R StroikDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America.
Delaine K CeholskiCardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York City, New York 10029, United States of America.
Philip A BidwellDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America; Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States of America.
Justyna MleczkoCardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York City, New York 10029, United States of America.
Paul F ThanelDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America.
Forum KamdarDivision of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States of America.
Joseph M AutryDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America.
Razvan L CorneaDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America.
David D ThomasDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America. Electronic address: ddt@umn.edu.
University of Minnesota · USIcahn School of Medicine at Mount Sinai · US
Funding
TRAINING PROGRAM IN MUSCLE RESEARCHT32AR007612 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JAMES M ERVASTI, DAWN A LOWE · 2001 to 2026
$11.3MStructural Dynamics of Muscle Calcium ATPase RegulationR01GM027906 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI THOMAS, DAVID D · 1985 to 2016
$8.6MStructural Dynamics of Muscle ContractionR01AR032961 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI THOMAS, DAVID D · 1986 to 2018
$8.0MNMR Structural Analysis of Calcium Regulation in MuscleR01GM064742 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI VEGLIA, GIANLUIGI · 2002 to 2019
$7.1MStructural Dynamics of Cardiac Muscle Calcium ATPase RegulationR01HL139065 · NHLBI · UNIVERSITY OF MINNESOTA · PI Robyn T Rebbeck, David D Thomas · 2020 to 2026
$5.2MSite-Directed Oxidative Modification of Muscle Protein Structural DynamicsR37AG026160 · NIA · UNIVERSITY OF MINNESOTA · PI THOMAS, DAVID D · 2011 to 2020
$4.5MCalcium Pump Activators for Heart Failure TherapyR01HL129814 · NHLBI · UNIVERSITY OF MINNESOTA · PI THOMAS, DAVID D · 2015 to 2018
$3.2MProtein Oxidation, Structure, &Function in Aging MuscleR01AG026160 · NIA · UNIVERSITY OF MINNESOTA TWIN CITIES · PI THOMAS, DAVID D · 2004 to 2008
$2.2MStructural Basis of Dilated CardiomyopathyR01HL144130 · NHLBI · UNIVERSITY OF MINNESOTA · PI VEGLIA, GIANLUIGI · 2018 to 2021
$1.5MNHLBI NIH HHS R01 HL129814NHLBI NIH HHS R01 HL139065NHLBI NIH HHS R01 HL144130NIAMS NIH HHS R01 AR032961NIAMS NIH HHS T32 AR007612NIA NIH HHS R01 AG026160NIA NIH HHS R37 AG026160NIGMS NIH HHS R01 GM027906
Abstract
There is increasing momentum toward the development of gene therapy for heart failure (HF) that is defined by impaired calcium (Ca
Indexed as
Binding, CompetitiveCalciumCalcium-Binding ProteinsCardiomyopathy, DilatedDependovirusFluorescence Resonance Energy TransferHEK293 CellsHumansInduced Pluripotent Stem CellsLoss of Function MutationMutationMyocytes, CardiacPhospholambanSarcoplasmic Reticulum Calcium-Transporting ATPasesCalciumCalcium-Binding ProteinsPhospholambanSarcoplasmic Reticulum Calcium-Transporting ATPasesCalcium transportCardiomyocyteDilated cardiomyopathyGene therapyPhospholambanSERCA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.